Continuous glucose monitoring in older inpatients with type 2 diabetes and cognitive impairment: an open single-arm feasibility study
Donat Ergin et al.
The finding, in our words
Continuous glucose monitoring using a wearable sensor was highly feasible and acceptable among older hospital inpatients with type 2 diabetes and cognitive impairment, with nearly all participants reporting no pain, ease of use, and convenience, suggesting the device could be suitable for this vulnerable population.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
A fully remote decentralised clinical trial in Danish adults with type 2 diabetes demonstrated operational feasibility with rapid recruitment, high retention (87 percent), and excellent adherence to continuous glucose monitoring (95 percent achieving ≥70 percent data coverage) and telemedicine visits (97 percent). Activity tracker adherence was poor (12 percent) due to technical issues, but remote safety monitoring was effective with no unexpected adverse events, supporting the viability of remote diabetes management.
In adults with type 1 diabetes, Dexcom G7 and FreeStyle Libre 3 showed high accuracy during physical activity, whereas the Simplera system was less accurate; this matters for selecting devices in decentralised monitoring.
Sanfilippo et al., Diabetes, obesity & metabolism · source ↗
In adults with MASLD, sucrose-free brazzein-sweetened ice cream produced smaller postprandial glucose excursions and lower incremental area under the curve over 150 min than sucrose-sweetened ice cream, measured by continuous glucose monitoring.
Isakov et al., Clinical nutrition ESPEN (paywalled) · source ↗
Over-the-counter continuous glucose monitors demonstrated reasonable agreement with overall capillary blood glucose trends in individuals without diabetes, yielding an overall mean absolute relative difference of 12.9%. However, sensor accuracy decreased following carbohydrate consumption, suggesting caution is required when using these devices for diagnostic cut-offs or exact-value monitoring.
Prakash et al., Journal of diabetes science and technology (paywalled) · source ↗
A review of hydrogel-based sensors for perioperative monitoring found that evidence remains predominantly preclinical, with no devices yet prospectively validated in dedicated perioperative patient cohorts. Translation to clinical practice requires standardised reference-method validation, stability testing, and regulatory integration.
Chen et al., International journal of nanomedicine · source ↗